CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 673 enrolled
Drug / intervention
Trastuzumab +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02091141
NCT02091141Phase 2Completed
CompareCT.gov

My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Genentech, Inc.·interventional·Posted Mar 19, 2014·Updated Jul 23, 2024

In Brief

A Phase 2 clinical trial evaluating Trastuzumab, Pertuzumab, and 6 other interventions for Neoplasms and 4 related conditions. Completed, enrolled 673 participants across 60 sites.

Detailed Summary

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 19, 2014
Enrollment StartApr 14, 2014
Primary CompletionMay 24, 2023
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 12.3 years ago

Interventions

Trastuzumabdrug

Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Pertuzumabdrug

Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Erlotinibdrug

Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Vemurafenibdrug

Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Cobimetinibdrug

Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Vismodegibdrug

Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Alectinibdrug

Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.

Atezolizumabdrug

Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.